iPhone app for vision tests wins FDA approval

Article

 

Richardson, TX-The FDA has approved use of the MyVisionTrack iPhone app from Vital Art and Science Inc. (VAS) to enable patients with retinal disease to monitor his or her vision between visits to the doctor. MyVisionTrack was developed for elderly patients with serious retinal diseases, such as age-related macular degeneration and diabetic retinopathy.

Mike Bartlett, president of VAS, said the app incorporates a proprietary shape discrimination hyperacuity test. The test consists of three circles, one of which is distorted. The app instructs patients to touch the circle that is different. "As they get it right, the distortion gets smaller; when they miss, the distortion gets bigger," Bartlett said. The test moves to the user's threshold until the distorted circle is no longer visible.

An algorithm determines a patient's vision threshold using statistics generated by the app. The app can store test results and monitor disease progression using the Apple device. In addition, MyVisionTrack automatically notifies a doctor if a patient's vision deteriorates significantly.

The approval consists of Class II prescription-only 510 (K) clearance for use on an iPhone 4S by prescription only. The app is unaffected by factors such as user distance.

For more information, go to http://myvisiontrack.com.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.